Skip to main
  1. Stocks
  2. Bioventus
  3. Forecast
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus is supported by a resilient core franchise in HA injections, bone graft substitutes, and fracture care, with Durolane showing rapid growth since its U.S. launch in 2018 and a leading position in single-injection pain treatment. Management also believes BGS can outgrow a low-single-digit market and that fracture care remains durable despite reimbursement pressure, while the company generated over $72 million in free cash flow in 2025, up from less than $38 million in 2024. The outlook is further strengthened by investments of about $13 million in 2026 across PNS, PRP, ultrasonics, and international, alongside +7.5% organic revenue growth in FY25, expanding adj. EBITDA margins above 20% in 2025, and continued debt reduction that should improve capital allocation flexibility.

Bears say

Bioventus is challenged by intense competition in spinal fusion and related musculoskeletal markets, where larger, better-capitalized rivals like Johnson & Johnson and Medtronic have broader product portfolios and stronger ability to win share. Its outlook is further pressured by dependence on FDA and other regulatory approvals, because delays or remediation can be costly and time-consuming, while reimbursement risk in the U.S. and abroad can reduce procedure volumes and pricing flexibility. The company’s acquisition-heavy strategy adds integration, execution, and potential dilution risk, and its efforts to expand the commercial network may not translate into sustainable productivity or financial improvement.

Bioventus (BVS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Bioventus (BVS) Analyst Forecast & Price Prediction

Get the latest Bioventus (BVS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Bioventus (BVS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 4 analysts, Bioventus (BVS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Bioventus (BVS) Analyst Forecast & Price Prediction

Get the latest Bioventus (BVS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Bioventus (BVS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BVS stock data and trends